Azhari Hala F
College of Medicine and Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Front Pharmacol. 2025 Jul 8;16:1581598. doi: 10.3389/fphar.2025.1581598. eCollection 2025.
Accurate cardiac adrenoceptor assessment is crucial for managing cardiovascular diseases. This study introduces a novel radiotracer, technetium-99m-labeled carvedilol ([Tc]Tc-carvedilol), which advances non-invasive cardiac receptor evaluation by improving traceability and myocardial tissue selectivity. Aimed at strengthening diagnostic precision, it optimizes a selective radioligand for quantifying cardiac adrenergic receptor sites.
[Tc]Tc-carvedilol was synthesized direct radiolabeling with technetium-99m, key parameters were optimized to maximize radiolabeling efficiency and ensure a reliable and reproducible [Tc]Tc-carvedilol complex. Biodistribution was rigorously evaluated and , emphasizing cardiac uptake, receptor occupancy, biodistribution, and clearance kinetics. Comparative analysis with [I]iodocarvedilol and Tc-sestamibi provided insights into advancements in detection efficiency and translational potential.
[Tc]Tc-carvedilol showed a radiolabeling efficiency of 96.5% ± 2.87%, with serum stability >92% at 24 h. Biodistribution studies in Swiss Albino mice (24 mice, aged 10-12 weeks, weighing 25 ± 3 g) revealed peak cardiac uptake (27.533% ± 0.931% injected dose per Gram of tissue (ID/g) within 15 min post-injection, alongside efficient blood clearance and minimal non-target tissue uptake (5.972% ± 0.131% ID/g organ) by 120 min. Docking analysis confirmed robust β-adrenoceptors (-9.2 kcal/mol) hydrogen bonds and hydrophobic and electrostatic interactions. Compared to [I]iodocarvedilol and Tc-sestamibi [Tc]Tc-carvedilol exhibited superior stability, targeting accuracy, and pharmacokinetics.
The enhanced selective cardiac uptake and favorable pharmacokinetics of [Tc]Tc-carvedilol position it as a promising agent for non-invasive cardiac receptor mapping, with the potential to improve diagnostic accuracy and specificity. Further clinical validation is essential to confirm its efficacy in detecting and evaluating cardiac pathologies.
准确评估心脏肾上腺素能受体对于心血管疾病的管理至关重要。本研究引入了一种新型放射性示踪剂,锝-99m标记的卡维地洛([Tc]Tc-卡维地洛),它通过提高可追溯性和心肌组织选择性推进了无创心脏受体评估。旨在提高诊断精度,它优化了一种用于定量心脏肾上腺素能受体位点的选择性放射性配体。
[Tc]Tc-卡维地洛通过用锝-99m直接放射性标记合成,关键参数经过优化以最大化放射性标记效率并确保可靠且可重复的[Tc]Tc-卡维地洛复合物。严格评估了生物分布,重点是心脏摄取、受体占有率、生物分布和清除动力学。与[I]碘卡维地洛和锝- sestamibi的比较分析提供了关于检测效率和转化潜力进展的见解。
[Tc]Tc-卡维地洛的放射性标记效率为96.5%±2.87%,24小时血清稳定性>92%。在瑞士白化小鼠(24只,10 - 12周龄,体重25±3克)中的生物分布研究显示,注射后15分钟内心脏摄取峰值为每克组织27.533%±0.931%注射剂量(ID/g),同时血液清除效率高,到120分钟时非靶组织摄取最小(5.972%±0.131% ID/g器官)。对接分析证实了与β-肾上腺素能受体有强大的相互作用(-9.2千卡/摩尔),通过氢键以及疏水和静电相互作用。与[I]碘卡维地洛和锝- sestamibi相比,[Tc]Tc-卡维地洛表现出卓越的稳定性、靶向准确性和药代动力学。
[Tc]Tc-卡维地洛增强的选择性心脏摄取和良好的药代动力学使其成为无创心脏受体成像的有前景的药物,有可能提高诊断准确性和特异性。进一步的临床验证对于确认其在检测和评估心脏病变中的疗效至关重要。